Market Overview

Shares Of Omeros Rocket Higher As Wedbush Lifts Target, Sees Near Tripling In Stock Price

Related OMER
Omeros Stock Remains Higher On Promising Kidney Drug Trial Data
Mid-Day Market Update: Insteel Industries Drops Following Q4 Results; DragonWave Shares Spike Higher
Biotech Forum Daily Digest: Biotech Slowly Recovering, Analysts Line Up Behind Omeros, Spotlight On Enanta Pharmaceuticals (Seeking Alpha)

Omeros (NASDAQ: OMER) shares spiked over the $11 technical level in morning trade Wednesday following a mid-day research note from Wedbush's Liana Moussatos. The stock is now up more than 16 percent for the session.

Moussatos boosted her fair value estimate on Omeros from $28 to $32 while reiterating an Outperform rating.

The Wedbush analyst said, "With U.S. and EU regulators formally accepting OMS302 for review, the time clock for approval begins. With a July 2013 submission and our anticipation of a 10-month U.S. review for the OMS302 NDA, we estimate a PDUFA date in May 2014."

Moussatos does not expect any delays given the recent "stellar" results from each Phase 3 trial of OMS302.

Moussatos is modeling for peak global gross sales for the product at around $500 million. She is anticipating a possible partnership and Phase 2 results for OMS824 by the end of 2013.

With Omeros shares last trading at $11.27, Moussatos new fair value estimate suggests potential upside of more than 180 percent.

Latest Ratings for OMER

Jun 2016Cantor FitzgeraldInitiates Coverage onBuy
Apr 2016Roth CapitalTerminatesBuy
Aug 2015Roth CapitalInitiates Coverage onBuy

View More Analyst Ratings for OMER
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Reiteration FDA Analyst Ratings Movers


Related Articles (OMER)

View Comments and Join the Discussion!